

TAVI- All the complications

Dr Kathy Lau









Severe Aortic Stenosis • Early intervention. • TTE: • 50% patient with AS die within 2 - Central role in evaluating severity years unless effective treatment of AS provided • CT key role: - Trend toward increasing waiting times - Evaluating feasibility of TAVI for SAVR - Determining risk of - Long waiting times for TAVI & significant complications. mortality awaiting intervention - Increasing heart failure-related hospitalisations ECHO

ECHO


Minimally invasive treatments- sedation TAVI


- Reduced use of ICU
- Quicker patient recovery
- Shorter length of hospital stay compared with surgical intervention
- Benefits are to reduce:
 - Capacity challenges related to staffing
 - Catheterization laboratory time
 - Waiting lists for beds.

5

6


Implications for assessment of complications 023) 32. 232-23 Minimalist approach: • **Dedicated Next Day Discharge Post** Minimalist TAVI: The Tasmanian 1 2022:47:1009 urr Pro Experience Next-Day Discharge vs Early **Discharge After Transcatheter Aortic** Scott Eaves, MBChB^{a,e}, Conor Lees, MBBS^a, David Jin, MD^a, Clare Rayner, MD^a, Sarang Paleri, MD^a, Stephanie Rowe, MI John Lee, MD^a, Umair Hayat, MBBS^a, Heath Adams, MBBS^{a,} Valve Replacement: Systematic MD^a. **Review and Meta-Analysis** Rahul Gupta^{®,e}, Sugandhi Mahajan^b, Anila Mehta^b, Mark Nyaeme^b, Nikhil A. Mehta⁵, Adil Cheema^b, Luna Khanal[®], Acqib H. Malik^d, Wilbert S. Aronow^d, Apurva V. Vyas⁰, Sanjay S. Mehta^{*}, and Nainesh C. Patel^a Department of Roval Hobart Hospital, Hobart, Tas, Av > Front Cardiovasc Med. 2023 Aug 14;10:1227217. doi: 10.3389/fcvm.2023.1227217. eCollection 2023. Contemporary European practice in transcatheter aortic valve implantation: results from the 2022 va, IL, ° European TAVI Pathway Registry . 2022 Oct 6;8(2):143-144. doi: 10.4244/AIJ-D-22-000 Liesbeth Rosseel ^{1,2}, Darren Mylotte ³, Bernard Cosyns ^{2,4}, Maarten Vanhaverbeke ⁵, David Zweiker ⁶, Rui Campante Teles ^{7,8}, Oskar Angerås ^{9,10}, Antoinette Neylon ¹¹, Tanja Katharina Rudolph ¹², Joanna J Wykrzykowska ¹³, Tiffany Patterson ¹⁴, Giulia Costa ¹⁵ Soledad Ojeda ¹⁶, Apostolos Tzikas ¹⁷, Marcel Abras ¹⁸, Lionel Leroux ¹⁹, Eric Van Belle ²⁰, Didier Tchétche ³¹, Sabine Bleiziffer ²², Marti J Swans ²³, Radoslaw Parma ²⁴, Daniel J Blackman ²⁵, Nicolas M Van Mieghem ²⁶, Marek Grygier ²⁷, Simon Redwood ¹⁴, Bernard Prendergast ¹⁴, Guy Van Camp ²⁸, Ole De Backer ²⁹ Impact of frailty on a minimalist approad discharge following TAVI Janarthanan Sathananthan ¹, Sandra B Lauck ¹, John Cairns ¹, Karin H Hur Madhu Natarajan ³, Harindra C Wijeysundera ⁴, David J Cohen ⁵, Martin B John G Webb ¹, David A Wood ¹ ECHO






Case selection for transesophageal imaging

- Heart team meeting
- All high-risk patients, not for SAVR
- Contraindication to contrastenhanced computed tomography (CT): renal failure
- Determinants intraprocedural TOE:
 - Anatomical indications
 - Patient risk factors: gastroesophageal abnormalities, severe pulmonary hypertension, severe LV dysfunction.







ЕСНО


APIEN 3 Stent Frame & Leaflets Balloon-expandable, cobalt-chromium Bovine pericardial leaflets Open cell design for coronary access TAVI valve types: nhanced Outer Sealing Skirt Textured PET material 40% increase height of the outer skirt • 2 types of transcatheter valves: - Balloon-expandable valve-• Third generation SAPIEN[™] valves (Edwards Lifesciences, USA) - SAPIEN 3 & SAPIEN 3 Ultra Resilia valves - Self-expandable valve-Evolut-Pro Evolut-R • CoreValve[™] (Medtronic, USA) • Evolut R, Evolut Pro & Evolut Pro+ valves (Medtronic, USA) • ACURATE TA (Symetis SA, Switzerland) 11


J. Clin. Mal. 2023, 12, 5645	r com	nplicat	tion	s wit	h re	cent	TA	VI Vá	alve	5 of 12	
Ta		the main TAVI compl	ications in stud			ter valves.					
	High-Intermediate-Risk Patients UK TAVI		Intermediate-Risk Patients PARTNER 2A SURTAVI			TAVI	Low Risk Patien PARTNER 3			EVOLUT	
	TAVI	SAVR	TAVI	SAVR	TAVI	SAVR	TAVI	SAVR	TAVI	SAVR	
Stroke	2.4	2.3	5.5	6.1	3.4	5.6	0.6	2.4	3.4	3.4	
PVL at least moderate	2.4	0.9	3.7	0.6	3.5	0.7	0.8	0	3.4	0.4	
Mild PVL	43.7	12.3	22.5	2.8	28.3	NA	28.7	4.2	36	3	
New pacemaker implantation	11	6.7	8.5	6.9	25.9	6.6	6.5	4	17.4	6.1	
Major vascular complications	10.1	2.3	7.9	5	6	1.1	2.2	1.5	3.8	3.2	
Aortic valve reintervention	2.2	1.1	1.4	0.6	2.8	0.7	0.6	0.5	0.7	0.6	
Severe PPM	NA	NA	NA	NA	NA	NA	NA	NA	1.1	4.4	
Coronary artery obstruction	NA	NA	0.4	0.6	0.2	0	0.2	0.7	0.9	0.4	
ar re	tery obstruction is repo	f patients. The incidence orted at 30days, with th d at the end of the stud	e exception of th	he UK TAVI trial, w	hen the incidenc	e and the severity	of PVL were rep	ported at 6 week	s. The incidenc	e of aortic valve	
	Review TAVI aff	ter More Than 20 Ye	ars, Postolach	e, et al., (2023) J	. Clin. Med., 12	, 5645. https://do	bi.org/10.3390	/jcm12175645			
Background AS ally invasive approach	TAVI types Complications										


J. Clin. Med. 2023, 12, 5645	able 2. Incidence of t	he main TAVI comp	lications in stud	lies with more re	ecent tran	es.		
	High-Intermedia	ate-Risk Patients		Intermediate-Risk Patients				
	UK	TAVI	PART	NER 2A	SURTAVI			
	TAVI	SAVR	TAVI	SAVR	TAVI	SAVR		
Stroke	2.4	2.3	5.5	6.1	3.4	5.6		
PVL at least moderate	2.4	0.9	3.7	0.6	3.5	0.7		
Mild PVL	43.7	12.3	22.5	2.8	28.3	NA		
New pacemaker implantation	11	6.7	8.5	6.9	25.9	6.6		
Major vascular complications	10.1	2.3	7.9	5	6	1.1		
Aortic valve reintervention	2.2	1.1	1.4	0.6	2.8	0.7		
Severe PPM	NA	NA	NA	NA	NA	NA		
Coronary artery obstruction	NA	NA	0.4	0.6	0.2	0		
ar re	umbers represent % of tery obstruction is reported intervention is reported rosthesis mismatch.	orted at 30days, with t d at the end of the stud	ne exception of th y period. TAVI, t	e UK TAVI trial, w ranscatheter aortic	when the incidenc	e and the sev		
TAVI hypes Complications						ECHO		
















Urgent TTE supine Hybrid Lab








































<section-header><section-header><list-item><list-item><list-item><list-item><list-item><list-item>

BICUSPID AORTIC VALVE


- Bulky irregular calcification affecting annulus
 + outflow tract
- Variants in commissural fusions (raphe)
- Larger annular dimensions
- Asymmetric cusps
- Aortopathy (dilation, coarctation or aneurysm)





International Consensus Statement on Nomenclature and Classification of the Congenital Bicuspid Aortic Valve developed to characterize, identify, and risk-stratify patients with a bicuspid aortic valve (BAV)





ECHO




































































TAVR for AR

Challenging due:

- 1. Anatomical issues, including a larger elliptical aortic annulus
- 2. Associated aorta or aortic root dilatation
- 3. Lack of annular calcification that can anchor THVs.

4. Larger stroke and regurgitant volume creates a "suction effect," impedes proper positioning.

